𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐂𝐚𝐧𝐚𝐝𝐚 𝐄𝐚𝐫𝐥𝐲 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐚𝐧𝐚𝐝𝐚 𝐄𝐚𝐫𝐥𝐲 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 is predicted to reach USD 124.39 million with a CAGR of 9.15% till 2030. Early toxicity testing is a pivotal procedure that involves assessing the potential harmful effects or toxicity of drugs, chemicals, or substances at their initial stages of development. 𝐊𝐞𝐲 𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬: 𝐍𝐨𝐧-𝐀𝐧𝐢𝐦𝐚𝐥 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐞𝐭𝐡𝐨𝐝𝐬 : There is an increasing shift in Canada towards non-animal testing methods for early-stage toxicity testing, driven by both ethical considerations and regulatory requirements. This includes the use of in vitro, organ-on-chip, and in silico models (computer simulations) that provide more human-relevant data compared to traditional animal testing. 𝐇𝐞𝐚𝐥𝐭𝐡 𝐂𝐚𝐧𝐚𝐝𝐚’𝐬 𝐅𝐨𝐜𝐮𝐬 𝐨𝐧 𝐒𝐚𝐟𝐞𝐭𝐲 : Regulatory bodies in Canada, such as Health Canada and the Canadian Environmental Assessment Agency (CEAA), are placing a growing emphasis on the development and use of alternative toxicity testing methods that align with international standards for reducing animal use in toxicity testing. https://www.nextmsc.com/report/canada-early-toxicity-testing-market